Cost‑Benefit of Trastuzumab Before Surgery in HER2 Breast Cancer
Breast cancer rates are climbing worldwide, but death numbers are falling thanks to smarter drugs. One of the toughest types shows too much HER2 protein, about 15 % of all cases. Doctors usually give the drug Trastuzumab after surgery to fight any remaining cancer cells. More and more patients are now receiving it before surgery, hoping to shrink the tumor first.
The New Question
How does giving Trastuzumab before surgery affect money and patient health?
A study examined three regimens:
| Regimen | Timing |
|---|---|
| Pre‑surgery only | Before operation |
| Post‑surgery only | After operation |
| Both | Pre‑ and post‑operation |
The goal was to find the best mix of health benefits and cost savings.
What Was Measured
- Complete tumor response (how many patients had no detectable cancer)
- Side‑effect rates
- Total treatment cost per patient
- Long‑term outcomes: survival, quality of life
By merging clinical data with financial figures, the researchers produced a clear picture of cost‑effectiveness.
Key Findings
- Pre‑surgery only
- Lowers the chance of cancer returning
Keeps costs lower than the combined approach
- Combined pre‑ and post‑surgery
- May be worth the extra expense for high‑risk patients due to better survival rates
Implications for Health Planning
- Resource allocation: Hospitals aiming to treat more patients without overspending may favor the pre‑surgery only option.
- Patient‑specific decisions: Aggressive cancers might justify the combined plan.
Bottom Line
Where and when a drug is used matters as much as the drug itself. By weighing health outcomes against costs, doctors and policymakers can make smarter choices that benefit patients and the system alike.
